Antitumor Activity by an Anti-CD44 Variant 9 Monoclonal Antibody in Gastric and Colorectal Cancer Xenograft Models
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26189170 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Mayuki Tawara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Colorectal Neoplasms, Stomach Neoplasms, Antibodies, Monoclonal. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development (AMED).
Abstract (Originalsprache)
CD44 variants (CD44v) play essential roles in the promotion of tumor metastasis, maintenance of cancer stem cell properties, and resistance to treatments. Therefore, the development of anti-CD44v mAbs is essential for targeting CD44v-positive tumor cells. An anti-CD44v9 mAb, C44Mab-1 (mouse, IgG1, kappa), was previously established. C44Mab-1 recognizes the variant exon 9-encoded region and applies to multiple research techniques. A mouse IgG2a version of C44Mab-1 (C44Mab-1-mG2a) was generated to evaluate the in vitro and in vivo antitumor activities using gastric and colorectal cancer cell lines. C44Mab-1-mG2a showed a reactivity to CD44v3–10-overexpressed Chinese hamster ovary-K1 (CHO/CD44v3–10), gastric cancer MKN45, and colorectal cancer COLO205 in flow cytometry. C44Mab-1-mG2a exhibited both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CHO/CD44v3–10, MKN45, and COLO205. Furthermore, administration of C44Mab-1-mG2a significantly suppressed CHO/CD44v3–10, MKN45, and COLO205 xenograft tumor growth compared with control mouse IgG2a. These results indicated that C44Mab-1-mG2a, which possesses ADCC/CDC activities, could be applied to the mAb-based therapy against CD44v9-positive carcinomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
- Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan.
ORCID-Profile: Hiroyuki Suzuki, Tomokazu Ohishi, Mika K Kaneko, Yukinari Kato
Förderung
- the Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development (AMED)
- Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI)
Zitieren
APA
Tawara, M., Suzuki, H., Ohishi, T., Kaneko, M. K., & Kato, Y. (2025). Antitumor Activity by an Anti-CD44 Variant 9 Monoclonal Antibody in Gastric and Colorectal Cancer Xenograft Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26189170
Vancouver
Tawara M, Suzuki H, Ohishi T, Kaneko MK, Kato Y. Antitumor Activity by an Anti-CD44 Variant 9 Monoclonal Antibody in Gastric and Colorectal Cancer Xenograft Models. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26189170
BibTeX
@article{Tawara2025,
author = {Tawara, Mayuki and Suzuki, Hiroyuki and Ohishi, Tomokazu and Kaneko, Mika K and Kato, Yukinari},
title = {Antitumor Activity by an Anti-CD44 Variant 9 Monoclonal Antibody in Gastric and Colorectal Cancer Xenograft Models},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26189170}
}
EUVIMED